Pipeline
| Product Candidate | Indication | Preclinical | Early-Stage Clinical | Late-Stage Clinical |
|---|---|---|---|---|
Nana-val (nanatinostat + valganciclovir) |
Relapsed/Refractory EBV+ Lymphoma | |||
Nana-val |
Recurrent/Metastatic EBV+ Solid Tumors | |||
Nana-val |
Multiple Sclerosis | |||
| Product Candidate | Indication | Stage |
|---|---|---|
| Nana-val (nanatinostat + valganciclovir) | Relapsed/Refractory EBV+ Lymphoma | Late-Stage Clinical |
| Nana-val | Recurrent/Metastatic EBV+ Solid Tumors | Early-Stage Clinical |
| Nana-val | Multiple Sclerosis | Preclinical |
EBV+: Epstein-Barr Virus Positive
Regulatory Status
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for nanatinostat in combination with valganciclovir for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoid malignancies.
- Orphan Drug Designations granted for nanatinostat with valganciclovir for the treatment of:
- T-cell lymphoma
- Post-transplant lymphoproliferative disorder (PTLD)
- Plasmablastic lymphoma
Viracta has initiated a clinical trial to treat EBV+ lymphomas. For more information about the trial, see ClinicalTrials.gov.
Contact: [email protected]
Viracta has an Expanded Access Policy in compliance with the 21st Century Cures Act.
